{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.014","statisticalMethod":"Exact Poisson calculation"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline.","groups":[{"description":"HPV 16 negative based on serum at visit 0 and DNA from visit 0 and 3 from any anatomical site.","id":"OG000","title":"Naive to HPV 16"},{"description":"HPV 16 positive based on serum at visit 0.","id":"OG001","title":"Prior Exposure to HPV 16"}],"paramType":"NUMBER","populationDescription":"Eligible participants without prevalent HPV 16 related HGAIN at baseline who received at least one vaccination and returned after month 7 with evaluable anal/perianal histology and PCR samples.","reportingStatus":"POSTED","timeFrame":"Post month 7 through month 24","title":"Incidence of HGAIN Associated With HPV 16","type":"PRIMARY","unitOfMeasure":"per 100 person years"}